GP方案联合康莱特注射液治疗晚期非小细胞肺癌的疗效及安全性分析  

Analysis of Efficacy and Safety of GP Scheme Plus Kanglaite Injection for Advanced Non-small Cell Lung Cancer

作　　者：杭猛[1] 陈暑波[1] 孙清[1] 赵帆[1] 

机构地区：[1]无锡市第二人民医院,214002

出　　处：《实用癌症杂志》2017年第2期289-291,共3页The Practical Journal of Cancer

摘　　要：目的探讨GP方案联合康莱特注射液治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法根据治疗方案将137例晚期NSCLC患者分为观察组(70例)与对照组(67例),观察组患者采用GP方案联合康莱特注射液治疗,对照组患者采用GP方案治疗,2个疗程化疗后对所有患者进行疗效以及不良反应评价。结果两组患者近期疗效比较差异无统计学意义(P>0.05)。化疗前两组患者CD3^+T细胞百分比、CD4^+T细胞百分比、CD8^+T细胞百分比、CD4^+/CD8^+比值比较差异无统计学意义(P>0.05);化疗后观察组上述指标水平均显著高于对照组,差异有统计学意义(P<0.05)。观察组粒细胞减少、血小板减少、贫血、恶心呕吐等不良反应级别均显著低于对照组,差异有统计学意义(P<0.05)。结论 GP方案联合康莱特注射液治疗晚期NSCLC可以改善患者免疫功能,降低化疗药物不良反应。Objective To explore the efficacy and safety of GP scheme plus Kanglaite injection in the treatment of ad-vanced non-small cell lung cancer（NSCLC）.Methods 137 cases of advanced NSCLC were divided into the observation group （70 cases） and the control group（67 cases） according to their therapeutic regimens ,and the observation group were treated with GP scheme plus Kanglaite injection ,while the control group were treated with GP scheme only .All patients were evaluated for effi-cacy and adverse reactions after 2 courses of chemotherapy .Results No obvious difference was found in the short-term efficacy between the 2 groups（P〉0.05）.Before chemotherapy,there were no obvious differences in the CD3 ＋T cells percentage,CD4＋T cells percentage,CD8 ＋T cells percentage and CD4 ＋/CD8 ＋ratio between the 2 groups（P〉0.05）.After chemotherapy,these be-fore-mentioned index levels in the observation group were obviously higher than those of the control group （P〈0.05）.The levels of granulocytopenia,thrombocytopenia,anemia,nausea and vomiting in the observation group were obviously lower those of the control group（P〈0.05）.Conclusion The GP scheme plus Kanglaite injection in the treatment of advanced NSCLC can im-prove immune function and reducing adverse reactions of chemotherapy drugs .

关 键 词：康莱特 吉西他滨 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]